- Home
- WHF vs MCRB Comparison
WHF vs MCRB Comparison
Compare WHF & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- MCRB
- Stock Information
- Founded
- WHF 2011
- MCRB 2010
- Country
- WHF United States
- MCRB United States
- Employees
- WHF N/A
- MCRB N/A
- Industry
- WHF Finance Companies
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- MCRB Health Care
- Exchange
- WHF Nasdaq
- MCRB Nasdaq
- Market Cap
- WHF 162.2M
- MCRB 144.8M
- IPO Year
- WHF 2012
- MCRB 2015
- Fundamental
- Price
- WHF $7.02
- MCRB $16.87
- Analyst Decision
- WHF Hold
- MCRB Hold
- Analyst Count
- WHF 3
- MCRB 3
- Target Price
- WHF $9.17
- MCRB $14.33
- AVG Volume (30 Days)
- WHF 149.6K
- MCRB 88.5K
- Earning Date
- WHF 11-10-2025
- MCRB 11-05-2025
- Dividend Yield
- WHF 25.36%
- MCRB N/A
- EPS Growth
- WHF N/A
- MCRB N/A
- EPS
- WHF 0.42
- MCRB 0.62
- Revenue
- WHF $76,339,000.00
- MCRB $351,000.00
- Revenue This Year
- WHF N/A
- MCRB N/A
- Revenue Next Year
- WHF N/A
- MCRB N/A
- P/E Ratio
- WHF $16.60
- MCRB $26.91
- Revenue Growth
- WHF N/A
- MCRB N/A
- 52 Week Low
- WHF $6.39
- MCRB $6.53
- 52 Week High
- WHF $11.31
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- WHF 47.32
- MCRB 51.80
- Support Level
- WHF $6.39
- MCRB $12.48
- Resistance Level
- WHF $7.40
- MCRB $14.35
- Average True Range (ATR)
- WHF 0.23
- MCRB 1.18
- MACD
- WHF -0.00
- MCRB 0.22
- Stochastic Oscillator
- WHF 61.88
- MCRB 80.50
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.